Akebia Therapeutics (AKBA) Change in Account Payables (2016 - 2026)
Akebia Therapeutics has reported Change in Account Payables over the past 10 years, most recently at $10.4 million for Q4 2025.
- Quarterly Change in Account Payables rose 335.21% to $10.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Dec 2025, up 325.95% year-over-year, with the annual reading at $3.1 million for FY2025, 325.95% up from the prior year.
- Change in Account Payables was $10.4 million for Q4 2025 at Akebia Therapeutics, up from -$8.8 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $18.9 million in Q4 2022 and troughed at -$13.8 million in Q3 2021.
- The 5-year median for Change in Account Payables is -$1.8 million (2022), against an average of -$688000.0.
- Year-over-year, Change in Account Payables crashed 272.51% in 2021 and then soared 491.65% in 2022.
- A 5-year view of Change in Account Payables shows it stood at $3.2 million in 2021, then soared by 491.65% to $18.9 million in 2022, then crashed by 76.2% to $4.5 million in 2023, then plummeted by 46.84% to $2.4 million in 2024, then skyrocketed by 335.21% to $10.4 million in 2025.
- Per Business Quant, the three most recent readings for AKBA's Change in Account Payables are $10.4 million (Q4 2025), -$8.8 million (Q3 2025), and $3.7 million (Q2 2025).